Beyond Air
Open
$0.51
Prev. Close
$0.51
High
$0.51
Low
$0.51
Market Snapshot
$4M
-0.1
-21.15
$3.02M
61
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
emptyResult
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Recently from Cashu
Modular, connected UV curing platform draws interest from medical-device firms like Beyond Air
Connected, modular device design that lowers downtime draws attention from medical device firms such as Beyond Air Modular, connected platforms reshaping device adoption American Pipelining Solutions…
APS debuts UV XAIR single‑head UV relining for 3–24" pipes at WWETT 2026
APS rolls out single-head UV curing for small-diameter relining American Pipelining Solutions (APS) is adding the UV XAIR ultraviolet (UV) curing system to its portfolio, bringing single-head, small-d…
Beyond Air: Request for Content to Summarize and Create Article
I apologize for the misunderstanding, but I need the actual content you want summarized in order to create an article based on it. Please provide the relevant text or information about Beyond Air, and…
Beyond Air Innovates Lung Delivery Technology for Enhanced Respiratory Treatments
Beyond Air Advances Lung Delivery Technology for Respiratory Treatments Beyond Air, a pioneering company in lung-targeted therapies, continues to make strides in its innovative approach to treating re…